ScinoPharm Changshu and Sundia MediTech Establish Strategic Alliance for Pharmaceutical Contract Research and Manufacturing in China
TAINAN, Aug. 7, 2013 /PRNewswire/ -- ScinoPharm (Changshu) Pharmaceuticals and Sundia MediTech Company Ltd. announced today a strategic alliance to seek more opportunities for collaboration on Contract Research and Manufacturing Services (CRAMS) in mainland China and to tap into this large and growing business potential.
Dr. Jo Shen, CEO of ScinoPharm Taiwan and Chairman of ScinoPharm Changshu, stated, "Resources from our Changshu site in Jiangsu province, China, and the Shanghai-based CRO company Sundia will be combined to establish a robust collaboration with single-source solutions to address the increasing number of multinational companies shifting their drug development research and clinical trials in China."
"Sundia has established long-standing and strong relationships with a number of big pharmaceuticals and small/ medium-sized biotech companies from the US, Europe, Japan and South Korea in the fields of chemistry, biology, preclinical formulation and API manufacture, helping our clients and partners to bring drugs to the market efficiently," said Dr. Chen Chen, Sundia's CEO. "Sundia is very pleased to have the opportunity to work with ScinoPharm, a world-leading process R&D and API manufacturing service provider. I am sure that the strategic partnership between Sundia and ScinoPharm will have mutual benefits, helping each other to thrive in both international and China Market. "
This cooperation combines Sundia's diversified technical know-how and capabilities in new drug R&D with ScinoPharm's process R&D and commercial production advantages, especially in the field of highly potent oncological APIs. Under the alliance, both parties will be able to further support customer needs with one-stop solutions for integrated services such as drug development, research, clinical trials and commercial manufacturing. Presently, China is one of the most preferred CRAMS destinations in Asia and is likely to witness substantial growth in this field as global R&D expenditures increase in outsourcing services, especially to China.
Founded by a group of veterans from the US biopharmaceutical industry in 2004, Sundia MediTech Company Ltd. is now a leading Shanghai-based Clinical Research Organization (CRO) providing drug discovery and development services worldwide with a research team of over 600 employees of which 70% have Ph.D. or MS degrees. It was named as one of the top 50 "most valuable companies for investment in China" in both 2007 and 2008 and ranked in the Deloitte Technology Fast 500 Asia Pacific list for 5 years in a row. Currently, Sundia has successfully established collaborations with over 100 client companies in North America, Europe, and Japan.
In response to the complex and challenging process involved in developing new drugs, ScinoPharm Changshu, in additional to providing Process R&D and Commercial Production to meet the global demand of generic APIs, also provides an interactive single-location custom synthesis service covering the entire R&D chain, from initial development to product launch. This includes optimization studies on synthesis technology, scale-up of product batch size, technology verification, and the supply of active pharmaceutical ingredients and intermediates from clinical study needs to commercial launch requirements. ScinoPharm Changshu also provides support with product registration and regulatory filings and addresses inquiries on GMP inspections and registration documents for both domestic and foreign drug regulators. The consolidated services are designed to satisfy all pharmaceutical needs of both domestic and overseas clients.
Founded in 2009, ScinoPharm Changshu is located at Changshu Economic Development Zone in Jiangsu Province. ScinoPharm Changshu is a subsidiary of ScinoPharm Taiwan Ltd., which is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and Mainland China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The Company also provides a vertically integrated, one-stop-shopping service for its API customers by expanding into the field of oncological injectable formulations. For more information, please visit the Company's website at http://www.scinopharm.com.
Founded by a group of veterans from the US pharmaceutical and biotech industry in 2004, Sundia MediTech Company Ltd. is now a leading Chinese CRO company providing quality, efficient, and cost-effective services in every stage of drug discovery and/ or pharmaceutical development, particularly in chemistry synthesis and pre-clinical studies. By August 2013, three INDs were approval by CFDA and one IND approval by US FDA through pre-clinical study collaborations with Sundia.
SOURCE ScinoPharm Taiwan, Ltd.
CONTACT: ScinoPharm, Sabrina Wu , Corporate Communications Manager, +886-6-508-2869, +886-920-056-385, [email protected]; Sundia, Li Zhao, Director of Global Business Development, +021-51098642-167, [email protected]
Web Site: http://www.scinopharm.com